期刊
DRUGS & AGING
卷 30, 期 10, 页码 783-792出版社
ADIS INT LTD
DOI: 10.1007/s40266-013-0108-6
关键词
-
资金
- Banner Sun Health Research Institute [NIA P30 AG 019610]
- Arizona Alzheimer's Research Consortium
To date, symptomatic medications prevail as the mainstay of treatment options for Alzheimer's disease (AD). There have been tremendous investments made to increase the numbers of drugs approved and the targets engaged, in an effort to alter the disease course or pathophysiology of AD. Unfortunately, almost all studies have not met expectations and no new drug (beyond medical foods) has been approved for the treatment of AD in the last decade. This review is a comparison of novel AD therapies in the late phases of clinical testing, including recent high-profile clinical failures, and agents in development with relatively unexplored mechanisms of action, with a focus on their potential as therapeutic agents and their proposed advantages over the treatments currently in use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据